A rationally designed Wuhan-sequence-based COVID-19 vaccine that maintained effectiveness against diverse SARS-CoV-2 variants, including Omicron: What was the key to success?

Abstract

The continuous emergence of SARS-CoV-2 variants of concern has highlighted important limitations of first-generation COVID-19 vaccines developed against the ancestral Wuhan spike protein. Although these vaccines provided strong protection against severe disease and mortality, the accumulation of mutations in the spike protein, particularly within the receptor-binding domain (RBD), progressively reduced their ability to prevent infection and facilitated immune escape. In contrast, vaccine approaches that combine multiple complementary viral antigens have shown greater potential to maintain broad protective immunity despite ongoing viral evolution and immune escape. In this article, we discuss the scientific basis of a plant-produced recombinant COVID-19 cocktail vaccine that demonstrated sustained immunogenicity and cross-variant effectiveness despite being designed from the ancestral Wuhan SARS-CoV-2 sequence. Based on our experimental studies, we propose that this broad protective potential results from the integration of three key design elements: (i) targeting conserved and functionally constrained epitopes within the RBD, (ii) combining RBD and nucleocapsid (N) proteins in a multi-antigen vaccine formulation, and (iii) applying glycoengineering strategies to optimize antigen structure and immune recognition, thereby broadening the immune response and reducing susceptibility to viral immune escape. We further discuss the advantages of plant molecular farming, particularly transient expression in Nicotiana benthamiana, as a rapid, scalable, and cost-effective platform for recombinant vaccine production. Our studies demonstrated that plant-produced glycosylated and deglycosylated RBD antigens retain functional receptor-binding activity and induce strong neutralizing antibody responses. Moreover, when combined with the N protein, these antigens maintained effectiveness against highly divergent SARS-CoV-2 variants, including Omicron. Importantly, the principles underlying this vaccine design may extend beyond COVID-19. The strategic combination of conserved and immunologically complementary antigens provides a rational framework for the development of broadly protective vaccines against future pandemic threats and other rapidly evolving emerging pathogens. In particular, our findings suggest that integrating conserved and immunologically complementary antigens may represent a universal vaccine design strategy to combat future pandemics caused by rapidly evolving pathogens.